News and events
- All
- Events
- Press releases
- Publications
- All
- Events
- Press releases
- Publications
Antibody Engineering & Therapeutics Europe 2023 – June 6-8, 2023 – Amsterdam, The Netherlands
Our Head of Preclinical Development is attending this event in person to meet the antibody community.
Read More
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike
Currently circulating SARS-CoV-2 variants have gained complete or significant resistance to all SARSCoV-2-neutralizing antibodies that have been used in the clinic. Such antibodies can prevent ...
Read More
Bio€quity Europe— May 12-14, 2023 – Dublin, Ireland
Excited to be a part of the Presenting Company Class of 2023 at BioEquity: Europe 2023!
Read More
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike Focus ...
Read More
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
xeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, today announced that it has secured a venture debt financing ...
Read More